Last Publications

(10/482)

  1. Chevalier, B, Ghander, C, Ladsous, M, Gaujoux, S, Taieb, D, Buffet, C et al.. What parathyroid imaging is required for hyperparathyroidism?. J Visc Surg. 2026; :. doi: 10.1016/j.jviscsurg.2026.07.018. PubMed PMID:42608243 .
  2. Bobot, M, Placier, S, Samson, C, Prignon, A, Louedec, L, Frère, P et al.. Acute Kidney Injury Induces Neurological Impairment Through Early Blood-Brain Barrier Disruption and Endothelial Transcytosis in Mice. Crit Care Med. 2026; :. doi: 10.1097/CCM.0000000000007285. PubMed PMID:42560137 .
  3. Long-Depaquit, T, Baboudjian, M, Peyrottes, A, Diamand, R, Ploussard, G. Patient Selection Matters: Who Is Represented in PROTEUS?. Eur Urol Oncol. 2026; :. doi: 10.1016/j.euo.2026.07.006. PubMed PMID:42527284 .
  4. Alavi, A, Revheim, ME, Newberg, AB, Werner, TJ, Guedj, E. 18F-Fluorodeoxyglucose PET, the Brain, and Other Organs: From the First Human Studies (1976) to 2026. PET Clin. 2026; :. doi: 10.1016/j.cpet.2026.05.001. PubMed PMID:42481350 .
  5. Berti, V, Fasciglione, E, Charpiot, A, Montanini, F, Pepponi, M, Leo, A et al.. Correction: Deciphering 18F-DOPA uptake in SDH-related head and neck paragangliomas: a radiomics approach. J Endocrinol Invest. 2026; :. doi: 10.1007/s40618-026-02985-2. PubMed PMID:42461578 .
  6. Sarrade, A, El Allam, J, Espinas, V, Hoffart, L, Picard, C, David, T et al.. Fast and compact scatterometer for ex vivo qualification of low-scattering biological samples. Rev Sci Instrum. 2026;97 (7):. doi: 10.1063/5.0327390. PubMed PMID:42439722 .
  7. Guedj, E, Beckman, D. Dopaminergic vulnerability in long COVID: striatal PET imaging at the brain-body interface. EBioMedicine. 2026;130 :106369. doi: 10.1016/j.ebiom.2026.106369. PubMed PMID:42431744 PubMed Central PMC13476893.
  8. Baboudjian, M, Barret, E, Brureau, L, Fiard, G, Fromont, G, Olivier, J et al.. Evidence thresholds for novel therapeutic strategies in prostate cancer: A consensus statement from the Prostate Cancer Committee of the French Urological Association. Fr J Urol. 2026;36 (9):103162. doi: 10.1016/j.fjurol.2026.103162. PubMed PMID:42413772 .
  9. Guedj, E, Newberg, AB, Alavi, A. Future Directions for [18F]FDG PET in Central Nervous System Diseases. PET Clin. 2026; :. doi: 10.1016/j.cpet.2026.06.003. PubMed PMID:42409693 .
  10. Guedj, E, Newberg, AB, Alavi, A. How Fluorine-18-labeled Fluorodeoxyglucose PET Changed Clinical Practice in Central Nervous System Disorders. PET Clin. 2026; :. doi: 10.1016/j.cpet.2026.06.002. PubMed PMID:42409692 .
Search PubMed